News
Buy Rating Affirmed for Merus with Promising Outlook on Petosemtamab’s Clinical and Market Potential
LifeSci Capital analyst Charles Zhu has maintained their bullish stance on MRUS stock, giving a Buy rating on September 30. Charles Zhu has given his Buy rating due to a combination of factors ...
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price target of $100.00. Charles Zhu has given his Buy rating due ...
LifeSci Capital analyst Charles Zhu has maintained their bullish stance on IDYA stock, giving a Buy rating yesterday. Charles Zhu has given his Buy rating due to a combination of factors that ...
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price target of $100.00. Don't Miss our Black Friday Offers ...
Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price target of $100.00. Charles Zhu has given his Buy rating due to a combination of ...
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Repare Therapeutics (RPTX – Research Report), with a price target of $8.00. Charles Zhu has given his Buy ...
Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Nuvalent (NUVL – Research Report). The associated price target remains the same with $110.00. Discover outperforming ...
Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target at $8.00. Charles Zhu has given his Buy rating due ...
LifeSci Capital analyst Charles Zhu has maintained their bullish stance on IDYA stock, giving a Buy rating on November 18. Don't Miss our Black Friday Offers: Charles Zhu’s rating is based on ...
LifeSci Capital analyst Charles Zhu maintained a Hold rating on Repare Therapeutics (RPTX – Research Report) today. The company’s shares opened today at $1.17. See what stocks are receiving ...
In a report released today, Charles Zhu from LifeSci Capital maintained a Hold rating on Repare Therapeutics (RPTX – Research Report). The company’s shares closed last Wednesday at $1.28.
Repare Therapeutics (RPTX – Research Report) received a Hold rating and price target from LifeSci Capital analyst Charles Zhu today. The company’s shares closed yesterday at $3.97. Pick the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback